Genmab — Maj 2017

[GeorgeBest]

Merck og britisk biotekselskab går ind på Genmab-område http://medwatch.dk/secure/Medicinal___Biotek/article9605506.ece?utm_campaign=Middag&utm_content=2017-05-26 12%3A16%3A03&utm_medium=top&utm_source=Feed

[bibob]

http://www.fiercebiotech.com/research/startup-tilos-to-develop-cancer-fighting-antibody-emerged-from-ms-research?mkt_tok=eyJpIjoiTXpnelkyUXlZekpsT1dVNCIsInQiOiJJQWhhSEVYM1ErY05weUd1d09hd091NWNXUGFSS2ZkU1R0REp4NjhQU1IxMGNTczhrS21MKzdIVnd0U0M2c2E4SVFjUXk2cWY2cEd6VTNrc3JJYkNENHBLQnc4V1czdVY3bHBcL09ZdkpwcFNsTStWRXFiWXQxazJiYnNjRVY3dnQifQ%3D%3D&mrkid=41140432&utm_medium=nl&utm_source=internal Er der ikke noget med at Dara også har vist effekt på T- cells. Kunne måske være lidt foran her. ?

[bibob]

God morgen efter en laaang weekend.

[Mayflower]

Godmorgen

[transalp]

Go morgen..

[Her_for_at_lære]

God Morgen

[Plimsoller]

Hvornår regner man med at Darzalex bliver godkendt til 1. linje behandling?

[JKY_VH]

Q12018 er mit bedste bud

[Sukkeralf]

Gætter på Q2

[Sukkeralf]

Og kun hvis data er fremragende som man forventer

[Plimsoller]

Ok. Tak.

[Sukkeralf]

3 linie

[E_L]

Article on european biotech in BioCentury featuring Genmab https://www.biocentury.com/biocentury/finance/2017-05-26/why-europe-may-have-what-it-takes-grow-new-generation-bellwethers

[flottenschmecker]

Nice article - buy before your neighbor!

[E_L]

or buy when your neighbour jumps out of the window - Genmab went a
bove 400 but then dropped to 25

[NextLifeDK]

Altså: 17. juni er deadline for svar på dara/pom/dex. Er det rigtigt forstået, Sukkeralf?

[Sukkeralf]

Ja Dara/Pom/Dex som tredie linie behandling - og på baggrund af et udvidet fase 1/2 studie.

[nik_hs1990]

Spændende Sukkeralf.

[gentogen]

RARA-high AML cell lines treated with SY-1425 and DARA were six fold more sensitive to NK cell mediated ADCC compared to single agent controls and exhibited a 5-10 fold increase in NK cell-dependent activation measured by IFNγ secretion....

[gentogen]

Since CD38 is one of the most strongly induced RARα target genes in response to SY-1425, AML blasts can be sensitized to DARA in a biomarker dependent manner. The preclinical synergistic effects and anticipated non-overlapping clinical toxicity profiles of the respective agents provide a strong rationale for clinical evaluation